Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

McLean Sibanda
Chief Executive Officer - The Innovation Hub

Second WIPO Inter-Regional Meeting on South-South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement

Organised by WIPO in cooperation with Ministry of Foreign Affairs of the Arab Republic of Egypt and Egyptian Academy of Scientific Research and Technology (ASRT)
6 – 8 May 2013 Cairo, Egypt
Overview

- Introduction
- TRIPS Agreement
- Patent Related Flexibilities
  - Defining
  - Key Patent-related Flexibilities
  - Research Exemption
  - Compulsory Licences
  - Constraints
- Concluding Remarks
Introduction
Changing Faces of Africa: New Challenges and Opportunities

Growing youth population: impact lifestyle & commerce.

Urbanization growth: 41% (2000-09)
Highest in the world

Economically active population: 70.7%
Highest in the world

Literacy growth: 8.5% (2000 -09)
Second Highest in the world

Changing demographics creating new challenges and opportunities

Fastest Growing mobile penetration
Introduction
Socio-economic Trends: Youthful Population

Growing youth population impacting lifestyle and commerce.

Economically active population: 70.7% Highest in the world

Source: AfDB based on UN Population Division data.
### Introduction

**Socio-Economic Trends: Mobile Connectivity**

#### Sub-Saharan Africa’s mobile opportunity

<table>
<thead>
<tr>
<th>Country</th>
<th>Mobile subscribers penetration rate, end 2012 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>136.8</td>
</tr>
<tr>
<td>S. Africa</td>
<td>134.3</td>
</tr>
<tr>
<td>Ghana</td>
<td>91.9</td>
</tr>
<tr>
<td>Zambia</td>
<td>78.9</td>
</tr>
<tr>
<td>Kenya</td>
<td>72.8</td>
</tr>
<tr>
<td>Nigeria</td>
<td>67.7</td>
</tr>
<tr>
<td>Cameroon</td>
<td>64.0</td>
</tr>
<tr>
<td>Tanzania</td>
<td>55.6</td>
</tr>
<tr>
<td>Uganda</td>
<td>48.4</td>
</tr>
</tbody>
</table>

Source: Strategy Analytics

- Figures can be more than 100% due to a person having more than one mobile.

---

**Opportunity for mobile to be a game changer:**

- **Enterprise level**
- **BOP applications**
- **Service Delivery**
Introduction
Socio-Economic Trends: Urbanisation

Urbanization growth: 41% (2000-09)
Highest in the world

Source: AfDB based on UN Population Division data.
# Introduction

World’s Fastest Growing Economies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Angola</td>
<td>11.1</td>
<td>China</td>
<td>9.5</td>
</tr>
<tr>
<td>China</td>
<td>10.5</td>
<td>India</td>
<td>8.2</td>
</tr>
<tr>
<td>Myanmar</td>
<td>10.3</td>
<td>Ethiopia</td>
<td>8.1</td>
</tr>
<tr>
<td>Nigeria</td>
<td>8.9</td>
<td>Mozambique</td>
<td>7.7</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>8.4</td>
<td>Tanzania</td>
<td>7.2</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>8.2</td>
<td>Vietnam</td>
<td>7.2</td>
</tr>
<tr>
<td>Chad</td>
<td>7.9</td>
<td>Congo</td>
<td>7.0</td>
</tr>
<tr>
<td>Mozambique</td>
<td>7.9</td>
<td>Ghana</td>
<td>7.0</td>
</tr>
<tr>
<td>Camboida</td>
<td>7.7</td>
<td>Zambia</td>
<td>6.9</td>
</tr>
<tr>
<td>Rwanda</td>
<td>7.6</td>
<td>Nigeria</td>
<td>6.8</td>
</tr>
</tbody>
</table>

Source: Economist, IMF, January 2011

Is it Sustainable?
Introduction
Health Challenges Facing Africa

People Living with HIV by Region, as Percent of Global Total, 2011

- Sub-Saharan Africa: 69%
- South/South-East Asia: 12%
- Eastern Europe/Central Asia: 4%
- Latin America: 4%
- North America: 4%
- Western/Central Europe: 3%
- East Asia: 2%
- Middle East/North Africa: 1%
- Caribbean: 0.7%
- Oceania: 0.2%

Introduction
Africa’s Low Technological Innovation Base
TRIPS AGREEMENT

Objectives

Article 7: Objectives

- IPR protection and enforcement should contribute to the promotion of technological innovation and to the transfer and dissemination of technology

- to the mutual advantage of producers and users of technological knowledge

- in a manner conducive to social and economic welfare, and to a balance of rights and obligations.
1. Members may, in formulating or amending their laws and regulations, adopt measures necessary to protect public health and nutrition, and to promote the public interest in sectors of vital importance to their socio-economic and technological development, provided that such measures are consistent with the provisions of this Agreement.

2. Appropriate measures, provided that they are consistent with the provisions of this Agreement, may be needed to prevent the abuse of intellectual property rights by right holders or the resort to practices which unreasonably restrain trade or adversely affect the international transfer of technology.
“In view of the special needs and requirements of least-developed country Members, their economic, financial and administrative constraints, and their need for flexibility to create a viable technological base ……”

Article 30 (TRIPS Agreement)

- Members can establish limited exceptions to the exclusive rights conferred by a patent

Cumulative 3-part test to comply with Art. 30

- Limited exception
- Not unreasonably conflict with normal exploitation
- Not unreasonably prejudice the legitimate interests of the patent owner
FLEXIBILITIES
Defining Flexibilities

Flexibilities

“there are **different options** through which **TRIPS obligations can be transposed into national law so that national interests are accommodated and yet TRIPS provisions and principles are complied with.**”  CDIP/5/4 Rev

Categories / Grouping of Flexibilities:

- Based on the point in time at which Members may resort to them:
  - i) in the **process of the acquisition of the right**
  - ii) **defining the scope of the right**
  - iii) **when enforcing the right**
FLEXIBILITIES
Key Patent Flexibilities / Exceptions

- **Flexibilities in the process of acquisition of the right**
  - Disclosure Related Flexibilities
  - Examination of Patent Applications
  - Patentability of Substances Existing in Nature

- **Flexibilities in defining the scope of the right**
  - Research exemption
  - Regulatory review exemption
  - Compulsory licensing and Government Use
  - Exhaustion of rights/Parallel Importation

- **Flexibilities when enforcing the right**
  - Ex-officio IP Office Control of Contractual Anti-competitive clauses
Canada-Patent Protection of Pharmaceutical Product case (DS114), defines the research exemption as:

- the exception under which **use of the patented product for scientific experimentation**, during the term of the patent and without consent, **is not an infringement**.

Rationale:

- “… exception is based on the notion that a key public policy purpose underlying patent laws is to facilitate the dissemination and advancement of technical knowledge and that allowing the patent owner to prevent experimental use during the term of the patent would frustrate part of the purpose of the requirement that the nature of the invention be disclosed to the public. To the contrary, the argument concludes, under the policy of the patent laws, both society and the scientist have a ‘legitimate interest’ in using the patent disclosure to support the advance of science and technology.”
FLEXIBILITIES
Compulsory Licensing

- An instrument to prevent abuses of the exclusivity and ensure wider application of patented subject matter
- **Safeguards for governments** to ensure public interest objectives, including national security, **public health** and to respond to national emergencies
- Ensure **fair exercise of patent rights** - encourage voluntary licenses at reasonable conditions
- Mechanism of **inducing competition**
- Seen as a tool to improve access to patented products / HIV drugs at reasonable prices within region
FLEXIBILITIES
Compulsory Licensing – Legislative Provisions

- Entitle the government, or a third party who is authorized by the government, to use the patented invention without authorization of the patentee under certain circumstances of public interest:
  - national security
  - nutrition
  - health or the development of other vital sectors of the national economy
  - remedies a patentee’s anti-competitive practice
### FLEXIBILITIES

**Compulsory Licensing – Scope of Legislative Provisions in National Laws, Examples**

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>PROVISION OF LAW</th>
<th>COMPULSORY LICENSING FOR NON-WORKING OF THE PATENT</th>
<th>COMPULSORY LICENSING FOR DEPENDENT PATENT</th>
<th>COMPULSORY LICENSE TO CORRECT PATENT ABUSE</th>
<th>COMPULSORY LICENSE FOR PUBLIC INTEREST</th>
<th>SEPARATE PROVISION ON GOVERNMENT USE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morocco</td>
<td>Articles 25-39 of Law No. 17-97 Concerning Protection of Industrial Property (Implemented by Decree No. 2-00-368 of 07/06/2004)</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Egypt</td>
<td>Articles 23 and 24 of the Law No. 82 of 2002</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>Sections 29-33 of the Proclamation of the Industrial Property Law No. 123 of the 10/05/1995</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
<td>Not explicitly provided</td>
<td>Not explicitly provided</td>
</tr>
<tr>
<td>Ghana</td>
<td>Sections 45- 52 of the Patents Law No. 305A of 30/12/1992</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
<td>Yes</td>
<td>Not explicitly provided</td>
</tr>
<tr>
<td>Kenya</td>
<td>Sections 72- 78 and 80 of the Industrial Property Act No. 3 of 27/07/2001</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
<td>Not explicitly provided</td>
<td>Yes</td>
</tr>
<tr>
<td>South Africa</td>
<td>Sections 55-56 of the Patents Act No. 57 of 1978 as last amended by Act No. 58 of 2002</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Not explicitly provided</td>
<td>Not explicitly provided</td>
</tr>
</tbody>
</table>
**ZAMBIA**

- September 21, 2004: Zambian Minister of Domestic Trade and Consumer Affairs issued a compulsory license.
- Patents for lamivudine, stavudine and nevirapine.
- CL granted to Pharco Ltd., a local producer, to produce a triple fixed-dose combination.
- Maximum royalty rate of 2.5% to apply.

**ZIMBABWE**

- May 2002: Zimbabwe's Minister of Justice, Legal and Parliamentary Affairs declared a Period of Emergency in order to override antiretroviral drug patents for a period of 6 months.
- Government use compulsory license to make, use or import generic HIV/AIDS medicines.
- 2003: Period of emergency extended by five years (to 31 December 2008).
- With assistance from India, Zimbabwe began local production of antiretrovirals through the generic company Varichem Pharmaceuticals (Private) Limited.

**FLEXIBILITIES**

**Compulsory Licensing – Some Examples**
FLEXIBILITIES
Compulsory Licensing – Some Examples

- SOUTH AFRICA
  - September 19, 2002 - Hazel Tau and TAC filed complaint with Competition Commission against GlaxoSmithKline (GSK) and Boehringer Ingelheim (GI)
  - Excessive pricing regarding ritonavir, lamivudine, nevirapine and ritonavir+lamivudine

- Commission ruling (October 16, 2003):
  - GSK and BI contravened the Competition Act of 1998.
  - abused their dominant positions in their respective anti-retroviral (ARV) markets
  - engaged in restrictive practices:
    - 1. Denied a competitor access to an essential facility
    - 2. Excessive pricing
    - 3. Engaged in an exclusionary act
FLEXIBILITIES
Compulsory Licensing – Some Examples

- (December 10, 2003)
- GSK/Competition Commission settlement
- BI followed suit thereafter
- Settlement based on voluntary licence

  - GSK Settlement
    1) Extend a voluntary licence granted to Aspen Pharmacare in October 2001 in respect of the public sector to include the private sector
    2) Grant up to three more voluntary licences on terms no less favourable than those granted to Aspen Pharmacare
    3) Permit licensees to export ARVs to sub-Saharan African countries
    4) Permit importation of the drugs for distribution in South Africa if licensee does not have manufacturing capability in South Africa
    5) Permit licensees to combine the relevant ARV with other antiretroviral medicines
    6) Charge royalties of no more than 5% of the net sales
FLEXIBILITIES

Constraints

- Domestic pharmaceutical manufacturing capacity
  - Reliance on importation which may not necessarily have desired price reduction and access
  - Need to build pharmaceutical research capability within the region

- Pressure against compulsory licences on basis of free trade

- Lack of awareness of patent system
  - Exhaustion of rights: Increased use of off-patent drugs
  - Exhaustion of rights: Territoriality of patents and in some cases, no patents in certain countries within region
  - Lack of technical capacity relating to negotiation / implementation of IP

- Technical capacity

- Bilateral agreements (e.g. AGOA) - need for caution
CONCLUDING REMARKS

- A number of countries have amended laws to include compulsory licence / government use

- Specific instances of use of compulsory licence / government use within region

- Use of flexibilities in the area of compulsory licences / government use, limited to public health or national emergencies

- In South Africa, voluntary licencing was fall back position, thereby preventing compulsory licensing
The Innovation Hub
Innovation Catalyst for a Smart Province: Gauteng, Republic of South Africa
www.theinnovationhub.com